A review of life science current events reported by MedCity News this week:
Medtronic CEO is GE Healthcare executive Omar Ishrak… and the analysts are pleased. Analyst Adam Feinstein of Barclays Capital wrote in a research note that Ishrak is a “good choice” for multiple reasons. First and foremost, he represents a “fresh face at a company where, in our view, investors were ready for a change.” His experience of running a large, successful, and diversified healthcare company also is a strength, as is “his track record of driving strong top and bottom line growth at GE Healthcare.”
SAS Institute launches healthcare industry think tank ‘CHAI.’ Business intelligence software giant SAS Institute is launching a health industry think tank to help hospitals, payors, drug companies and others navigate the growing role that analytics and statistics play throughout the health sector.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Medtronic’s MR-Conditional pacemaker likely too expensive, says analyst. An analyst who attended the Heart Rhythm Society meeting in San Francisco (May 4-7) believes that Medtronic is likely charging $3,000 more for the Revo SureScan MR Conditional pacemaker than previous pacemakers. Physicians at the conference, however, believe that Medtronic may be erring in pricing the device so high even though it leads the market in this device category, said David Lewis, a Morgan Stanley analyst, in a note to investors Monday.
Ohio father behind ‘Emily’s Law’ to publicly forgive pharmacist. An Ohio father whose 2-year-old daughter’s 2006 death spurred the passage of “Emily’s Law” is preparing to publicly forgive the pharmacist who went to prison for a medical error that led to the death. Chris Jerry, who has since started the Emily Jerry Foundation to raise awareness of medication errors, said he plans to forgive Eric Cropp in an interview next week for a segment on the Discovery Channel about patient safety.
Acorn Cardiovascular liquidates; former president leads new venture. Steve Anderson, Acorn’s former president, will not identify the cardiovascular company that bought Acorn’s intellectual property, or how much it sold for. But Anderson is already on to a new medical device venture.
